FREE Case Review (866) 588-0600

Abilify Lawsuit Filed in Massachusetts

A woman who claims to have suffered compulsive behavior including gambling, shopping and binge eating as a result of her use of the antipsychotic drug Abilify has filed a lawsuit against the manufacturers.

A Massachusetts woman who allegedly experienced uncontrollable compulsive behaviors after taking Abilify (generic: aripiprazole) has filed a personal injury lawsuit against Bristol-Myers Squibb and Otsuka Pharmaceutical.

Free Confidential Lawsuit Evaluation: If you or a loved one experienced compulsive behaviors after taking Abilify, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against the manufacturer and our lawyers can help.

What’s the Problem?

July 28, 2016 – According to the lawsuit, Abilify caused Plaintiff Rikki Carlson of Fall River, Mass., to have compulsive behaviors including gambling, shopping and binge eating, which caused her significant financial, mental and physical damages. Carlson says she started taking Abilify around December 2010, and began compulsively gambling and shopping shortly thereafter; these behaviors ceased promptly after she discontinued treatment with the drug in March 2016, according to the complaint.

Plaintiff further maintains that as a direct result of her use of Abilify, she suffered monetary losses of more than $40,000, loss of financial stability, significant weight gain, and other mental, physical and economic losses. The suit contends that the effect Abilify had on Carlson’s brain constitutes a physical injury, and that as a result of her use of the drug, she has suffered, and will continue to suffer extreme neuropsychiatric and physical injury, emotional distress, harm and economic damages.

While the labeling of Abilify in Europe has warned about a potential increased risk of “pathological gambling” since 2012, the same warning was not applied to the drug’s label in the U.S. until earlier this year. On May 3, 2016, the U.S. Food & Drug Administration (FDA) announced new warnings regarding “compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex” would be added to Abilify labels in the U.S. The agency recommended that prescribing doctors “make patients and caregivers aware of the risk of these uncontrollable urges,” “closely monitor” patients, and consider reducing or discontinuing treatment with the medication if compulsive behaviors appear.

Carlson alleges that Bristol-Myers and Otsuka unjustly profited at the expense of patient safety and full disclosure to the medical community by failing to warn about Abilify’s association with gambling, despite their obligation to do so. The complaint notes that as a result, defendants have made significantly greater profits from Abilify sales in the U.S. compared to overseas.

The lawsuit was filed Monday in the U.S. District Court for the District of Massachusetts, alleging claims of Strict Liability, Breach of Express Warranty, Breach of Implied Warranty, Negligence, Negligence Per Se, Negligent Misrepresentation, and Fraudulent Concealment, and seeks costs of treatment for plaintiff’s injuries, damages for her pain and suffering, mental and emotional anguish, as well as punitive damages.

Do I Have an Abilify Lawsuit?

The Pharmaceutical Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Abilify lawsuits. We are handling individual litigation nationwide and currently accepting new compulsive gambling cases in all 50 states.

Free Confidential Case Evaluation: Again, if you or a loved one experienced financial loss, family problems or legal consequences as a result of compulsive gambling while taking Abilify, you should contact our law firm immediately. You may be entitled to a settlement by filing a suit and we can help.

Free Confidential Case Evaluation

Verified 100% Secure SiteTo contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (866) 588-0600.
Awards & recognition